Clear Harbor Asset Management LLC Purchases 104 Shares of Amgen Inc. (NASDAQ:AMGN)

Clear Harbor Asset Management LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,371 shares of the medical research company’s stock after purchasing an additional 104 shares during the period. Clear Harbor Asset Management LLC’s holdings in Amgen were worth $2,442,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Lmcg Investments LLC lifted its holdings in shares of Amgen by 0.7% during the fourth quarter. Lmcg Investments LLC now owns 37,404 shares of the medical research company’s stock worth $9,749,000 after buying an additional 257 shares during the last quarter. Solidarity Wealth LLC bought a new position in Amgen during the fourth quarter worth $1,098,000. Crossmark Global Holdings Inc. raised its stake in Amgen by 2.6% during the 4th quarter. Crossmark Global Holdings Inc. now owns 76,607 shares of the medical research company’s stock valued at $19,967,000 after purchasing an additional 1,966 shares during the last quarter. Royal Fund Management LLC boosted its holdings in Amgen by 32.7% in the 4th quarter. Royal Fund Management LLC now owns 20,077 shares of the medical research company’s stock valued at $5,346,000 after purchasing an additional 4,942 shares during the period. Finally, Mitchell & Pahl Private Wealth LLC grew its position in Amgen by 13.0% in the 4th quarter. Mitchell & Pahl Private Wealth LLC now owns 5,879 shares of the medical research company’s stock worth $1,532,000 after purchasing an additional 676 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on AMGN. Redburn Partners lowered their price objective on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Leerink Partners dropped their target price on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Royal Bank of Canada decreased their price target on Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. Finally, Sanford C. Bernstein began coverage on Amgen in a research note on Thursday, October 17th. They set an “outperform” rating and a $380.00 price objective for the company. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $314.91.

Amgen Trading Up 1.0 %

AMGN opened at $272.11 on Tuesday. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The firm’s fifty day moving average is $273.95 and its two-hundred day moving average is $307.18. The firm has a market cap of $146.27 billion, a PE ratio of 34.84, a price-to-earnings-growth ratio of 2.78 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same period in the prior year, the company earned $4.96 earnings per share. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year. Equities research analysts anticipate that Amgen Inc. will post 19.57 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.50%. Amgen’s dividend payout ratio is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.